Skip to main content

Table 3 Efficacy in Subgroups Defined by Type of Previous Treatment Received

From: Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study

 

Prior Steroid

Prior Anti-VEGF

Prior Laser

Endpoint

DEX 0.7

Sham

DEX 0.7

Sham

DEX 0.7

Sham

 

n = 58

n = 61

n = 25

n = 26

n = 231

n = 243

Patients with BCVA ≥15-letter improvement from baseline at study end, %

27.6

8.2

28.0

7.7

21.2

11.9

Mean BCVA average change from baseline during the study (SD), lettersa

+4.9 (7.4)

−0.6 (8.6)

+4.2 (8.8)

+1.6 (7.6)

+3.1 (8.7)

+1.6 (7.5)

Mean CRT average change from baseline during the study (SD), μma

−121 (150)

−30 (135)

−130 (95)

−42 (123)

−123 (130)

−39 (121)

  1. aArea-under-the-curve approach
  2. BCVA best-corrected visual acuity, CRT central retinal thickness, DEX 0.7 dexamethasone intravitreal implant 0.7 mg, SD standard deviation